IDXX - IDEXX Laboratories, Inc.
286.75 0.00 (0.00%)
After hours: 4:42PM EST
| Previous Close | 288.78 |
| Open | 288.38 |
| Bid | 270.00 x 800 |
| Ask | 286.72 x 1100 |
| Day's Range | 285.76 - 289.35 |
| 52 Week Range | 198.75 - 294.57 |
| Volume | 289,560 |
| Avg. Volume | 481,059 |
| Market Cap | 24.598B |
| Beta (5Y Monthly) | 0.80 |
| PE Ratio (TTM) | 58.64 |
| EPS (TTM) | 4.89 |
| Earnings Date | Apr 28, 2020 - May 03, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 303.60 |
- Zacks
Ecolab (ECL) Earnings and Revenues Miss Estimates in Q4
Strength in the Global Industrial arm drives Ecolab's (ECL) Q4 results.
- PR Newswire
IDEXX Laboratories to Present at Two Upcoming Institutional Investor Conferences
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, will participate in two upcoming conferences:
- Zacks
AMN Healthcare (AMN) Q4 Earnings and Revenues Top Estimates
AMN Healthcare's (AMN) Q4 results gain from core Nurse and Allied Solutions units.
- Zacks
Luminex (LMNX) Earnings and Revenues Beat Estimates in Q4
Luminex's (LMNX) fourth-quarter earnings benefit from higher revenues and solid performance across System Sales, Service and Other Revenues. However, gross margin contraction remains a woe.
- Zacks
DaVita (DVA) Earnings Beat Estimates in Q4, Revenues Miss
DaVita (DVA) gains from dialysis services in the United States in Q4.
- Simply Wall St.
Is There Now An Opportunity In IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
IDEXX Laboratories, Inc. (NASDAQ:IDXX) saw a decent share price growth in the teens level on the NASDAQGS over the...
- Kiplinger
The 9 Best 'Purebred' Pet Stocks to Buy
America's love affair with its pets is creating a booming pet care industry - and, as a result, a small but expanding cluster of pet stocks.Pet care might be bigger than you realize. Edge by Ascential, a market research firm, says that North American spending on pets hit $225 billion in 2018, and is expected to hit $281 billion by 2023 - roughly 5% compound annual growth. Millennials and Gen-Zers are embracing pet ownership in far greater numbers than previous generations; roughly two-thirds of U.S. households own a pet, up from 56% just 30 years ago.Rising demand is fueling a diverse set of pet stocks - companies that provide everything from premium kibble to medications to even pet DNA testing and health insurance.You can get some pet-related exposure among blue chips such as General Mills (GIS), which acquired all-natural pet-food leader Blue Buffalo for $8 billion in 2018. Aon (AON) boasts a top-rated pet insurance business in the form of subsidiary Healthy Paws; Synchrony Financial (SYF) bought a principal rival, Pet's Best, in 2019. However, pet care remains a small portion of their overall business.Here, we look at nine of the best pure-play pet stocks to buy right now. This is a mix of high-growth newcomers and a few more established plays. We'll start with a couple of well-known blue chips before making our way to some under-the-radar names. SEE ALSO: 64 Dividend Stocks You Can Count on in 2020
- Zacks
Has IDEXX Laboratories (IDXX) Outpaced Other Medical Stocks This Year?
Is (IDXX) Outperforming Other Medical Stocks This Year?
- Zacks
Cardinal Health (CAH) Q2 Earnings & Revenues Top Estimates
Cardinal Health (CAH) fiscal second-quarter results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.
- Zacks
Becton, Dickinson (BDX) Q1 Earnings Beat, Revenues Rise Y/Y
Becton, Dickinson (BDX) sees softness in BD Medical unit, slashes FY20 view.
- Zacks
ABIOMED (ABMD) Earnings Beat Estimates in Q3, Revenues Miss
Flagship Impella drives ABIOMED's (ABMD) fiscal third-quarter results; FY20 revenue guidance slashed.
- Thomson Reuters StreetEvents
Edited Transcript of IDXX earnings conference call or presentation 31-Jan-20 1:30pm GMT
Q4 2019 IDEXX Laboratories Inc Earnings Call
- Zacks
Here's Why You Should Retain IDEXX Laboratories Stock Now
Investor confidence remains high in IDEXX (IDXX) stock, thanks to solid prospects.
- Zacks
DexCom (DXCM) Hits Fresh High: Is There Still Room to Run?
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
- Zacks
IDEXX (IDXX) Q4 Earnings Top Estimates, Revenues Grow Y/Y
The year-over-year upside in IDEXX's (IDXX) revenues was primarily driven by strong global gains in CAG Diagnostics' recurring revenues.
- Zacks
Idexx Laboratories (IDXX) Beats Q4 Earnings and Revenue Estimates
Idexx (IDXX) delivered earnings and revenue surprises of 14.29% and 0.92%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- Investing.com
IDEXX Labs Earnings, Revenue Beat in Q4
Investing.com - IDEXX Labs (NASDAQ:IDXX) reported on Friday fourth quarter earnings that beat analysts' forecasts and revenue that topped expectations.
- Zacks
Earnings Preview: Idexx Laboratories (IDXX) Q4 Earnings Expected to Decline
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
What's in Store for IDEXX Laboratories' (IDXX) Q4 Earnings?
IDEXX's (IDXX) is likely to report strong earnings for Q4, courtesy of a global surge in CAG Diagnostic revenues.
- Zacks
IDEXX Launches Cytology Service to Upgrade Veterinary Care
IDEXX (IDXX) upgrades veterinary care experience by launching a rapid digital cytology service, thus enabling the provision of faster results.
- Zacks
S&P 500 Up 1000 Points in a Month: 10 Stocks Boosted the ETF
The S&P 500 touched the 3,300 mark on Jan 16, having added 1000 points in less than a month. Which stocks led to the ETF rally.
- CNW Group
IDEXX Launches Rapid Digital Cytology Service to Further Accelerate Delivery of Veterinary Healthcare
WESTBROOK, Maine , Jan. 17, 2020 /CNW/ -- IDEXX Laboratories, Inc. (IDXX), a global leader in veterinary diagnostics and software, today announced that it is launching a new rapid digital cytology service that digitally connects veterinarians to the largest global network of more than 100 veterinary clinical pathologists and enables them to receive cytology interpretations within 2 hours. Powered by a new in-clinic instrument and IDEXX's proprietary VetConnect® PLUS software, the service will be available 24 hours a day, 7 days a week, 365 days a year. IDEXX Digital Cytology™ will be available to IDEXX customers in North America by mid-February.
- PR Newswire
Latest IDEXX Innovations Designed to Enhance Patient Care and Drive Veterinary Productivity
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics and software, today announced the latest updates to its SediVue Dx® Urine Sediment Analyzer, Catalyst Dx® and Catalyst One® chemistry analyzers, and IDEXX Web PACS™ cloud-based diagnostic imaging software, expanding the capabilities of each platform. These updates are designed to provide diagnostic tools that enhance patient care and drive productivity for veterinary teams by removing key workflow constraints.
